TGTX Earnings

TGTX reported its FY2025Q3 earnings on 2025-11-03, showcasing a revenue of 162.00M against an estimate of 152.00M, resulting in a 6.37% surprise. The EPS was 2.43, surpassing the expected 0.24 by 912.5% . The stock experienced a -3.13% price change on the earnings day and a -4.37% change over the next five days, reflecting market reactions to the results.

Following TGTX's FY2025Q3 earnings announcement on 2025-11-03, the stock price moved by -3.13% on the day of the release. Over the subsequent five days, it saw a -4.37% change. Historically, TGTX's stock price tends to shift by an average of +5.78% in the 10 days leading up to earnings and +6.35% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate TGTX’s annual revenue to reach 182.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 3.05% and EPS estimates Revise Upward by 4.88% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between TGTX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 3.05%, while EPS estimates moved Revise Upward by 4.88% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, TGTX's stock price typically moves by +5.78% in the 10 days before its earnings and +6.35% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 182.00M.

The earnings call summary highlights strong financial performance with significant growth in revenue and net income. The company's strategic initiatives, like the development of subcutaneous BRIUMVI and market expansion efforts, are promising. The Q&A section reveals optimism about future growth, despite some uncertainties in competitive dynamics and lack of specific guidance for 2026. The raised revenue guidance and strong market share growth for BRIUMVI further support a positive outlook. Overall, these factors suggest a likely positive stock price movement in the short term.